Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2010 Results
Date:11/3/2010

rnal body clock and the 24-hour environmental light/dark cycle.

Vanda has also initiated a one-year safety study of tasimelteon for the treatment of N24HSWD.  This is an open-label safety study that will enroll approximately 140 patients with N24HSWD.  Vanda plans to conduct additional clinical trials over the next one to two years to support U.S. and European regulatory submissions.  Tasimelteon was granted orphan drug designation by the FDA on January 19, 2010. The application for orphan designation from the European Medicines Agency is pending.

On October 29, 2010, Vanda received certification for qualified research and development investments under the Internal Revenue Service's Therapeutic Discovery Project Credit Program and will receive a cash payment of approximately $0.5 million.

FINANCIAL DETAILS-Revenues decreased by $1.1 million from $8.3 million for the third quarter of 2010 due to an increase of $0.4 million in royalty revenue offset by a decrease of $1.5 million in product revenue.  During the second quarter of 2010, the company sold the remaining Fanapt® inventory to Novartis.  -Cost of sales for the third quarter of 2010 was $0.4 million resulting from the amortization of the capitalized intangible asset related to the milestone payment to Novartis, compared to cost of sales for the second quarter of 2010 of $1.9 million, consisting of $0.4 million resulting from the amortization of the capitalized intangible asset related to the milestone payment to Novartis and $1.5 million for inventory sold to Novartis.Research and development (R&D) expenses were $4.1 million for the third quarter of 2010, compared to $2.4 million for the second quarter of 2010 and $2.1 million for the third quarter of 2009.  The increase in R&D expenses in the third quarter of 2010 relative to the second quarter of 2010 is primarily due to costs incurred in connection with the preparation of the Phase III trial
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  ResMed Inc. (NYSE: RMD ) today ... for the quarter was $423.0 million, a 10 percent increase ... percent increase on a constant currency basis). Net income was ... quarter ended December 31, 2013. Diluted earnings per share for ...
(Date:1/22/2015)... , Jan. 22, 2015  Bio-Techne Corporation (NASDAQ: ... Ella, the first member of the new Simple Plex ... brand.  This launch represents the re-branding of the previously ... Simple Plex platform is a transformative immunoassay technology which ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( ... "Infectious Disease Diagnostics Market by Product, Application, Technology, End ... their offering. , The infectious disease diagnostics ... to reach $18,156.2 million by 2019 from $12,422.8 million ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... ... , ... , , , ... ...
... , ... ... ... ...
Cached Medicine Technology:Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 2Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 3Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 4Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 5An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 2An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 3An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 4An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 5An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 6
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... that a mother,s nutrition during pregnancy can strongly influence her ... international study, led by University of Southampton researchers and including ... first time that during pregnancy, a mother,s diet can alter ... change, can lead to her child tending to lay down ...
... YORK, NY, April 15, 2011) Many genes that cause ... Now Columbia University researchers have used an innovative yeast-based screening ... disease Niemann-Pick C (NP-C). This "exacerbate-reverse" approach can potentially be ... in the Journal of Chemical Biology on April ...
... low incomes or chronic health problems -- who enroll ... cutting back on needed health care than other people who ... study. The findings, from the largest national study to ... the earlier small studies that found medically vulnerable individuals cut ...
... University of Calgary are investigating a new tool to use ... digital tool will help give patients a more accurate assessment ... doctors recommend the best treatment options. Currently, ... early-stage breast cancer is tumour grade, a score assigned by ...
... Despite steadily improving methods for its diagnosis and treatment, cancer still ... What is less well known is that this also holds ... 4,000 dogs in Austria develop cancer and about half the dogs ... is biologically similar to a human tumour. CEA is one ...
... 2011) -- Non-Hispanic black infants born with heart defects ... years of life than their non-Hispanic white and Hispanic ... Hispanic children as well as non-Hispanic black children fare ... in a new study by researchers at the University ...
Cached Medicine News:Health News:New link between mother's pregnancy diet and offspring's chances of obesity found 2Health News:Innovative screening method identifies possible new treatment for fatal childhood disease 2Health News:Innovative screening method identifies possible new treatment for fatal childhood disease 3Health News:High-deductible health plans pose no special risks to the medically vulnerable, study finds 2Health News:High-deductible health plans pose no special risks to the medically vulnerable, study finds 3Health News:Breast cancer prognosis goes high tech 2Health News:Minorities born with heart defects at higher risk of dying in early childhood than whites 2Health News:Minorities born with heart defects at higher risk of dying in early childhood than whites 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: